Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 108

1.

Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.

Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, Maison-Blanche P, Merkel M, Niederau C, Plӧckinger U, Richter J, Stulnig TM, Vom Dahl S, Cox TM.

Eur J Intern Med. 2016 Aug 10. pii: S0953-6205(16)30217-5. doi: 10.1016/j.ejim.2016.07.011. [Epub ahead of print] Review.

2.

Unexpected macrophage-independent dyserythropoiesis in Gaucher disease.

Reihani N, Arlet JB, Dussiot M, Billette de Villemeur T, Belmatoug N, Rose C, Colin-Aronovicz Y, Hermine O, Le Van Kim C, Franco M.

Haematologica. 2016 Jul 28. pii: haematol.2016.147546. [Epub ahead of print]

3.

Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks.

Hollak CE, Biegstraaten M, Baumgartner MR, Belmatoug N, Bembi B, Bosch A, Brouwers M, Dekker H, Dobbelaere D, Engelen M, Groenendijk MC, Lachmann R, Langendonk JG, Langeveld M, Linthorst G, Morava E, Poll-The BT, Rahman S, Rubio-Gozalbo ME, Spiekerkoetter U, Treacy E, Wanders R, Zschocke J, Hagendijk R.

Orphanet J Rare Dis. 2016 Jan 25;11:7. doi: 10.1186/s13023-016-0383-5.

4.

Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis.

Puéchal X, Pagnoux C, Perrodeau É, Hamidou M, Boffa JJ, Kyndt X, Lifermann F, Papo T, Merrien D, Smail A, Delaval P, Hanrotel-Saliou C, Imbert B, Khouatra C, Lambert M, Leské C, Ly KH, Pertuiset E, Roblot P, Ruivard M, Subra JF, Viallard JF, Terrier B, Cohen P, Mouthon L, Le Jeunne C, Ravaud P, Guillevin L; French Vasculitis Study Group.

Arthritis Rheumatol. 2016 Mar;68(3):690-701. doi: 10.1002/art.39450.

PMID:
26473755
5.

Understanding the natural history of Gaucher disease.

Mistry PK, Belmatoug N, vom Dahl S, Giugliani R.

Am J Hematol. 2015 Jul;90 Suppl 1:S6-11. doi: 10.1002/ajh.24055. Review.

6.

Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.

Jallouli M, Galicier L, Zahr N, Aumaître O, Francès C, Le Guern V, Lioté F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Le Thi Huong D, Asli B, Kahn JE, Pourrat J, Sailler L, Ackermann F, Papo T, Sacré K, Fain O, Stirnemann J, Cacoub P, Leroux G, Cohen-Bittan J, Sellam J, Mariette X, Blanchet B, Hulot JS, Amoura Z, Piette JC, Costedoat-Chalumeau N; Plaquenil Lupus Systemic Study Group.

Arthritis Rheumatol. 2015 May;67(8):2176-84. doi: 10.1002/art.39194.

7.

Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.

Stirnemann J, Rose C, Serratrice C, Dalbies F, Lidove O, Masseau A, Pers YM, Baron C, Belmatoug N.

Orphanet J Rare Dis. 2015 May 13;10:62. doi: 10.1186/s13023-015-0275-0.

8.

Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?

Fedida B, Touraine S, Stirnemann J, Belmatoug N, Laredo JD, Petrover D.

Eur Radiol. 2015 Oct;25(10):2969-75. doi: 10.1007/s00330-015-3715-2. Epub 2015 Apr 16.

PMID:
25875285
9.

[Acid sphingomyelinase deficiency and spleen trauma: splenectomy or not splenectomy?].

Lidove O, Le Fèvre L, Goasguen N, Jamali M, Vercellino L, Garnier M, Khellaf M, Belmatoug N, Ziza JM.

Rev Med Interne. 2015 Sep;36(9):619-22. doi: 10.1016/j.revmed.2014.10.367. Epub 2014 Nov 5. French.

PMID:
25479761
10.

Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial.

Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, Le Moing V, Belmatoug N, Lesprit P, Bru JP, Therby A, Bouhour D, Dénes E, Debard A, Chirouze C, Fèvre K, Dupon M, Aegerter P, Mulleman D; Duration of Treatment for Spondylodiscitis (DTS) study group.

Lancet. 2015 Mar 7;385(9971):875-82. doi: 10.1016/S0140-6736(14)61233-2. Epub 2014 Nov 5.

PMID:
25468170
11.

Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up.

Schoindre Y, Jallouli M, Tanguy ML, Ghillani P, Galicier L, Aumaître O, Francès C, Le Guern V, Lioté F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Le Thi Huong D, Asli B, Kahn JE, Sailler L, Ackermann F, Papo T, Sacré K, Fain O, Stirnemann J, Cacoub P, Leroux G, Cohen-Bittan J, Hulot JS, Lechat P, Musset L, Piette JC, Amoura Z, Souberbielle JC, Costedoat-Chalumeau N; Group PLUS.

Lupus Sci Med. 2014 Jun 7;1(1):e000027. doi: 10.1136/lupus-2014-000027. eCollection 2014.

12.

Behcet's disease in Budd-Chiari syndrome.

Desbois AC, Rautou PE, Biard L, Belmatoug N, Wechsler B, Resche-Rigon M, Zarrouk V, Fantin B, de Chambrun MP, Cacoub P, Valla D, Saadoun D, Plessier A.

Orphanet J Rare Dis. 2014 Sep 13;9:104. doi: 10.1186/s13023-014-0153-1. eCollection 2014.

13.

Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.

Vigan M, Stirnemann J, Caillaud C, Froissart R, Boutten A, Fantin B, Belmatoug N, Mentré F.

Orphanet J Rare Dis. 2014 Jun 30;9:95. doi: 10.1186/1750-1172-9-95.

14.

Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.

Serratrice C, Bengherbia M, Alessandrini M, Grosbois B, Camou F, Pers YM, Bismuth M, Marie I, Belmatoug N, Berger M; Comité d'Evaluation et de Traitement de la maladie de Gaucher.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):94-6. doi: 10.1016/j.bcmd.2013.12.004. Epub 2014 Jan 7. No abstract available.

PMID:
24411065
15.

A prospective study of bone marrow hematopoietic and mesenchymal stem cells in type 1 Gaucher disease patients.

Lecourt S, Mouly E, Freida D, Cras A, Ceccaldi R, Heraoui D, Chomienne C, Marolleau JP, Arnulf B, Porcher R, Caillaud C, Vanneaux V, Belmatoug N, Larghero J.

PLoS One. 2013 Jul 25;8(7):e69293. doi: 10.1371/journal.pone.0069293. Print 2013.

16.

Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide.

Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, Aumaitre O, Piette JC, Pourrat J, Boutin D, Sacre K, Kahn JE, Duhaut P, Farge D, Francès C, Guettrot-Imbert G, Harlé JR, Lambotte O, Le Guern V, Sène D, Trad S, Vidal E, Sarrot-Reynauld F, Gompel A, Tanguy ML, Touraine P, Lacorte JM, Costedoat-Chalumeau N; PLUS group.

J Clin Endocrinol Metab. 2013 Sep;98(9):3785-92. doi: 10.1210/jc.2013-1235. Epub 2013 Jul 5.

PMID:
23833039
17.

Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.

Jallouli M, Francès C, Piette JC, Huong du LT, Moguelet P, Factor C, Zahr N, Miyara M, Saadoun D, Mathian A, Haroche J, De Gennes C, Leroux G, Chapelon C, Wechsler B, Cacoub P, Amoura Z, Costedoat-Chalumeau N; Plaquenil LUpus Systemic Study Group.

JAMA Dermatol. 2013 Aug;149(8):935-40. doi: 10.1001/jamadermatol.2013.709.

PMID:
23824340
18.

Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.

Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, Couret M, Bouvard B, Debandt M, Gueit I, Gendre JP, Leone J, Nicolas N, Che D, Mariette X, Lortholary O; Research Axed on Tolerance of Biotherapies Group.

Chest. 2013 Sep;144(3):990-8. doi: 10.1378/chest.12-2820.

PMID:
23744173
19.

Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study.

Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, Brand M, Muller A, Schaaf B, Giorgino R, Zimran A.

Blood Cells Mol Dis. 2013 Aug;51(2):116-24. doi: 10.1016/j.bcmd.2013.04.005. Epub 2013 May 14.

PMID:
23683771
20.

Abnormal properties of red blood cells suggest a role in the pathophysiology of Gaucher disease.

Franco M, Collec E, Connes P, van den Akker E, Billette de Villemeur T, Belmatoug N, von Lindern M, Ameziane N, Hermine O, Colin Y, Le Van Kim C, Mignot C.

Blood. 2013 Jan 17;121(3):546-55. doi: 10.1182/blood-2012-07-442467. Epub 2012 Dec 3.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk